SUPPLEMENT

Q1 2025 — Financial disclosures

Q1 2025PDF · 9 pages821 KB
Merck & Co., Inc.
Financial Highlights Package
First Quarter 2025
Table of Contents
Table 1: 	GAAP P&L ..........................................................................1
Table 1a: GAAP P&L – Current Year and Prior Year by Quarter ...... 2
Table 2a: GAAP to Non-GAAP Reconciliation 1Q25 ........................... 3
Table 2b: GAAP to Non-GAAP Reconciliation 1Q24 ........................... 4
Table 3: 	Sales – Current Year and Prior Year by Quarter ................ 5
Table 3a: Sales – U.S. / International 1Q25 ............................................6
Table 3b: Sales – Pharmaceutical Geographic Split .......................... 7
Table 4: 	Other (Income) Expense..................................................... 8

-- 1 of 9 --

Sales 	15,529	$ 	15,775	$ 	-2%
Costs, Expenses and Other
Cost of sales 	3,419 	3,540 	-3%
Selling, general and administrative 	2,552 	2,483 	3%
Research and development 	3,621 	3,992 	-9%
Restructuring costs 	69 	123 	-44%
Other (income) expense, net 	(35) 	(33) 	6%
Income Before Taxes 	5,903 	5,670 	4%
Income Tax Provision 	818 	903
Net Income 	5,085 	4,767 	7%
Less: Net Income Attributable to Noncontrolling Interests 	6 	5
Net Income Attributable to Merck & Co., Inc. 	5,079	$ 	4,762	$ 	7%
Earnings per Common Share Assuming Dilution 	2.01	$ 	1.87	$ 	7%
Average Shares Outstanding Assuming Dilution 	2,531 	2,544
Tax Rate 	13.9% 	15.9%
MERCK & CO., INC.
CONSOLIDATED STATEMENT OF INCOME - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 1
GAAP
% Change
1Q25 	1Q24
1

-- 2 of 9 --

Sales 	15,529	$ 	15,775	$ 	16,112	$ 	16,657	$ 	15,624	$ 	64,168	$ 	-2%
Costs, Expenses and Other
Cost of sales 	3,419 	3,540 	3,745 	4,080 	3,828 	15,193 	-3%
Selling, general and administrative 	2,552 	2,483 	2,739 	2,731 	2,864 	10,816 	3%
Research and development 	3,621 	3,992 	3,500 	5,862 	4,585 	17,938 	-9%
Restructuring costs 	69 	123 	80 	56 	51 	309 	-44%
Other (income) expense, net 	(35) 	(33) 	42 	(162) 	126 	(24) 	6%
Income Before Taxes 	5,903 	5,670 	6,006 	4,090 	4,170 	19,936 	4%
Income Tax Provision 	818 	903 	545 	929 	425 	2,803
Net Income 	5,085 	4,767 	5,461 	3,161 	3,745 	17,133 	7%
Less: Net Income Attributable to Noncontrolling Interests 	6 	5 	6 	4 	2 	16
Net Income Attributable to Merck & Co., Inc. 	5,079	$ 	4,762	$ 	5,455	$ 	3,157	$ 	3,743	$ 	17,117	$ 	7%
Earnings per Common Share Assuming Dilution 	2.01	$ 	1.87	$ 	2.14	$ 	1.24	$ 	1.48	$ 	6.74	$ 	7%
Average Shares Outstanding Assuming Dilution 	2,531 	2,544 	2,544 	2,541 	2,537 	2,541
Tax Rate 	13.9% 	15.9% 	9.1% 	22.7% 	10.2% 	14.1%
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
%
Change
4Q 	1Q	Full Year
2025
1Q 	1Q 	2Q 	3Q
2024
MERCK & CO., INC.
CONSOLIDATED STATEMENT OF INCOME - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 1a
2

-- 3 of 9 --

First Quarter
Cost of sales 	3,419	$ 	620 	36 	656 	2,763	$
Selling, general and administrative 	2,552 	23 	23 	2,529
Research and development 	3,621 	7 	7 	3,614
Restructuring costs 	69 	69 	69 	–
Other (income) expense, net 	(35) 	(3) 	(107) 	(110) 	75
Income Before Taxes 	5,903 	(647) 	(105) 	107 	(645) 	6,548
Income Tax Provision (Benefit) 	818 	(117) (3) 	(18) (3) 	22 (3) 	(113) 	931
Net Income 	5,085 	(530) 	(87) 	85 	(532) 	5,617
Net Income Attributable to Merck & Co., Inc. 	5,079 	(530) 	(87) 	85 	(532) 	5,611
Earnings per Common Share Assuming Dilution 	2.01	$ 	(0.21) 	(0.03) 	0.03 	(0.21) 	2.22	$
Tax Rate 	13.9% 	14.2%
Only the line items that are affected by non-GAAP adjustments are shown.
The company is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends.
Management believes that providing non-GAAP information enhances investors’ understanding of the company’s results because management uses non-GAAP measures to assess performance. Management
uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, annual employee compensation, including senior
management’s compensation, is derived in part using a non-GAAP pretax income metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for or superior to,
information prepared in accordance with GAAP.
(1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect integration, transaction and
certain other costs related to acquisitions and divestitures. Amounts included in research and development expenses reflect the amortization of intangible assets.
(2) Amounts primarily include employee separation costs, accelerated depreciation and asset impairments associated with facilities to be closed or divested related to activities under the company's formal
restructuring programs.
(3) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments.
MERCK & CO., INC.
FIRST QUARTER 2025 GAAP TO NON-GAAP RECONCILIATION
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 2a
GAAP 	Acquisition- and Divestiture-
Related Costs (1) 	Restructuring Costs (2)	
(Income) Loss from
Investments in Equity
Securities
Adjustment Subtotal 	Non-GAAP
3

-- 4 of 9 --

First Quarter
Cost of sales 	3,540	$ 	463 	116 	579 	2,961	$
Selling, general and administrative 	2,483 	21 	5 	26 	2,457
Research and development 	3,992 	16 	2 	18 	3,974
Restructuring costs 	123 	123 	123 	–
Other (income) expense, net 	(33) 	(4) 	(116) 	(120) 	87
Income Before Taxes 	5,670 	(496) 	(246) 	116 	(626) 	6,296
Income Tax Provision (Benefit) 	903 	(92) (3) 	(42) (3) 	25 (3) 	(109) 	1,012
Net Income 	4,767 	(404) 	(204) 	91 	(517) 	5,284
Net Income Attributable to Merck & Co., Inc. 	4,762 	(404) 	(204) 	91 	(517) 	5,279
Earnings per Common Share Assuming Dilution 	1.87	$ 	(0.16) 	(0.08) 	0.04 	(0.20) 	2.07	$
Tax Rate 	15.9% 	16.1%
Only the line items that are affected by non-GAAP adjustments are shown.
MERCK & CO., INC.
FIRST QUARTER 2024 GAAP TO NON-GAAP RECONCILIATION
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
GAAP 	Acquisition- and Divestiture-
Related Costs (1) 	Restructuring Costs (2)	
(Income) Loss from
Investments in Equity
Securities
Table 2b
(3) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments.
Adjustment Subtotal 	Non-GAAP
The company is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends.
Management believes that providing non-GAAP information enhances investors’ understanding of the company’s results because management uses non-GAAP measures to assess performance. Management uses non-
GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, annual employee compensation, including senior management’s
compensation, is derived in part using a non-GAAP pretax income metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for or superior to, information prepared in
accordance with GAAP.
(1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect integration, transaction and certain other
costs related to acquisitions and divestitures. Amounts included in research and development expenses primarily reflect the amortization of intangible assets. Amounts included in other (income) expense, net, primarily
reflect royalty income related to the prior termination of the Sanofi-Pasteur MSD joint venture.
(2) Amounts primarily include employee separation costs, accelerated depreciation and asset impairments associated with facilities to be closed or divested related to activities under the company's formal restructuring
programs.
4

-- 5 of 9 --

MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3
2025 	2024 	1Q
1Q 	1Q 	2Q 	3Q 	4Q 	Full Year 	Nom % 	Ex-Exch %
TOTAL SALES (1) 	$15,529 	$15,775 	$16,112 	$16,657 	$15,624 	$64,168 	-2 	1
PHARMACEUTICAL 	13,638 	14,006 	14,408 	14,943 	14,042 	57,400 	-3 	-1
Oncology
Keytruda 	7,205 	6,947 	7,270 	7,429 	7,836 	29,482 	4 	6
Alliance Revenue – Lynparza (2) 	312 	292 	317 	337 	365 	1,311 	7 	8
Alliance Revenue – Lenvima (2) 	258 	255 	249 	251 	255 	1,010 	1 	2
Welireg 	137 	85 	126 	139 	160 	509 	62 	63
Alliance Revenue – Reblozyl (3) 	119 	71 	90 	100 	110 	371 	68 	68
Vaccines (4)
Gardasil/Gardasil 9 	1,327 	2,249 	2,478 	2,306 	1,550 	8,583 	-41 	-40
ProQuad/M-M-R II/Varivax 	539 	570 	617 	703 	594 	2,485 	-5 	-5
Vaxneuvance 	230 	219 	189 	239 	161 	808 	5 	7
RotaTeq 	228 	216 	163 	193 	139 	711 	5 	7
Capvaxive 	107 	47 	50 	97 	- 	-
Pneumovax 23 	41 	61 	59 	68 	74 	263 	-33 	-30
Hospital Acute Care
Bridion 	441 	440 	455 	420 	449 	1,764 	- 	1
Prevymis 	208 	174 	188 	208 	215 	785 	19 	22
Dificid 	83 	73 	92 	96 	79 	340 	13 	13
Zerbaxa 	70 	56 	62 	64 	70 	252 	24 	27
Cardiovascular
Winrevair 	280 	70 	149 	200 	419 	- 	-
Alliance Revenue - Adempas/Verquvo (5) 	106 	98 	106 	102 	109 	415 	8 	8
Adempas (6) 	68 	70 	72 	72 	73 	287 	-3 	1
Virology
Lagevrio 	102 	350 	110 	383 	121 	964 	-71 	-69
Isentress/Isentress HD 	90 	111 	89 	102 	92 	394 	-19 	-17
Delstrigo 	67 	56 	60 	65 	69 	249 	19 	24
Pifeltro 	45 	42 	39 	42 	40 	163 	7 	7
Neuroscience
Belsomra 	50 	46 	53 	78 	45 	222 	8 	13
Immunology
Simponi 	184 	172 	189 	543 	-100 	-100
Remicade 	39 	35 	41 	114 	-100 	-100
Diabetes (7)
Januvia 	549 	419 	405 	278 	232 	1,334 	31 	33
Janumet 	247 	251 	224 	204 	255 	935 	-2 	2
Other Pharmaceutical (8) 	729 	632 	618 	638 	699 	2,590 	16 	18
ANIMAL HEALTH 	1,588 	1,511 	1,482 	1,487 	1,397 	5,877 	5 	10
Livestock 	924 	850 	837 	886 	889 	3,462 	9 	16
Companion Animal 	664 	661 	645 	601 	508 	2,415 	- 	3
Other Revenues (9) 	303 	258 	222 	227 	185 	891 	17 	16
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
(7) Total Diabetes sales were $876 million in the first quarter of 2025 and $745 million in the first quarter of 2024.
(8) Includes Pharmaceutical products not individually shown above.
(9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues,
including revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were $95
million in the first quarter of 2025 and $61 million in the first quarter of 2024.
(1) Only select products are shown.
(2) Alliance Revenue represents the company's share of profits, which are product sales net of cost of sales and commercialization costs.
(3) Alliance Revenue represents royalties.
(4) Total Vaccines sales were $2,607 million in the first quarter of 2025 and $3,424 million in the first quarter of 2024.
(5) Alliance Revenue represents the company's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales
and commercialization costs.
(6) Net product sales in the company's marketing territories.
5

-- 6 of 9 --

MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES
FIRST QUARTER 2025
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3a
Global 	U.S. 	International
1Q 2025 	1Q 2024 	% Change 	1Q 2025 	1Q 2024 	% Change 	1Q 2025 	1Q 2024 	% Change
TOTAL SALES (1) 	$15,529 	$15,775 	-2 	$8,522 	$7,478 	14 	$7,007 	$8,297 	-16
PHARMACEUTICAL 	13,638 	14,006 	-3 	7,927 	6,936 	14 	5,711 	7,070 	-19
Oncology
Keytruda 	7,205 	6,947 	4 	4,308 	4,119 	5 	2,897 	2,828 	2
Alliance Revenue – Lynparza (2) 	312 	292 	7 	145 	135 	7 	168 	157 	7
Alliance Revenue – Lenvima (2) 	258 	255 	1 	186 	173 	8 	72 	82 	-12
Welireg 	137 	85 	62 	123 	77 	59 	15 	7 	98
Alliance Revenue – Reblozyl (3) 	119 	71 	68 	101 	58 	72 	18 	12 	47
Vaccines (4)
Gardasil/Gardasil 9 	1,327 	2,249 	-41 	536 	488 	10 	790 	1,761 	-55
ProQuad/M-M-R II/Varivax 	539 	570 	-5 	423 	438 	-3 	116 	133 	-12
Vaxneuvance 	230 	219 	5 	139 	161 	-14 	92 	58 	59
RotaTeq 	228 	216 	5 	164 	149 	10 	64 	67 	-4
Capvaxive 	107 	- 	106 	- 	1 	-
Pneumovax 23 	41 	61 	-33 	-2 	6 	-126 	42 	55 	-23
Hospital Acute Care
Bridion 	441 	440 	- 	378 	329 	15 	63 	111 	-43
Prevymis 	208 	174 	19 	102 	74 	37 	106 	100 	6
Dificid 	83 	73 	13 	72 	68 	6 	11 	5 	117
Zerbaxa 	70 	56 	24 	42 	33 	27 	28 	23 	20
Cardiovascular
Winrevair 	280 	- 	268 	- 	12 	-
Alliance Revenue - Adempas/Verquvo (5) 	106 	98 	8 	97 	90 	8 	9 	8 	12
Adempas (6) 	68 	70 	-3 	68 	70 	-3
Virology
Lagevrio 	102 	350 	-71 	35 	45 	-21 	67 	305 	-78
Isentress/Isentress HD 	90 	111 	-19 	51 	50 	2 	39 	61 	-35
Delstrigo 	67 	56 	19 	15 	12 	28 	52 	44 	17
Pifeltro 	45 	42 	7 	32 	29 	8 	13 	13 	2
Neuroscience
Belsomra 	50 	46 	8 	13 	15 	-10 	37 	32 	16
Immunology
Simponi 	184 	-100 	184 	-100
Remicade 	39 	-100 	39 	-100
Diabetes (7)
Januvia 	549 	419 	31 	344 	183 	88 	204 	236 	-13
Janumet 	247 	251 	-2 	65 	39 	68 	182 	212 	-14
Other Pharmaceutical (8) 	729 	632 	16 	184 	165 	12 	545 	467 	17
ANIMAL HEALTH 	1,588 	1,511 	5 	502 	474 	6 	1,086 	1,037 	5
Livestock 	924 	850 	9 	194 	166 	17 	730 	683 	7
Companion Animal 	664 	661 	- 	308 	308 	- 	356 	354 	1
Other Revenues (9) 	303 	258 	17 	93 	68 	37 	210 	190 	11
(6) Net product sales in the company's marketing territories.
(7) Total Diabetes sales were $876 million and $745 million on a global basis in the first quarter of 2025 and 2024, respectively.
(8) Includes Pharmaceutical products not individually shown above.
(9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues,
including revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were $95
million in the first quarter of 2025 and $61 million in the first quarter of 2024.
Sum of U.S. plus international may not equal global due to rounding.
(1) Only select products are shown.
(2) Alliance Revenue represents the company's share of profits, which are product sales net of cost of sales and commercialization costs.
(3) Alliance Revenue represents royalties.
(4) Total Vaccines sales were $2,607 million and $3,424 million on a global basis in the first quarter of 2025 and 2024, respectively.
(5) Alliance Revenue represents the company's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales
and commercialization costs.
6

-- 7 of 9 --

MERCK & CO., INC.
PHARMACEUTICAL GEOGRAPHIC SALES
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3b
2025 	2024 	% Change
1Q 	1Q 	2Q 	3Q 	4Q 	Full Year 	1Q
TOTAL PHARMACEUTICAL 	$13,638 	$14,006 	$14,408 	$14,943 	$14,042 	$57,400 	-3
United States 	7,927 	6,936 	7,399 	8,227 	7,728 	30,290 	14
% Pharmaceutical Sales 	58.1% 	49.5% 	51.4% 	55.1% 	55.0% 	52.8%
Europe (1) 	2,384 	2,555 	2,572 	2,620 	2,498 	10,246 	-7
% Pharmaceutical Sales 	17.5% 	18.2% 	17.9% 	17.5% 	17.8% 	17.9%
China (2) 	668 	1,744 	1,790 	996 	864 	5,394 	-62
% Pharmaceutical Sales 	4.9% 	12.5% 	12.4% 	6.7% 	6.2% 	9.4%
Japan 	651 	802 	664 	919 	813 	3,199 	-19
% Pharmaceutical Sales 	4.8% 	5.7% 	4.6% 	6.2% 	5.8% 	5.6%
Latin America 	589 	601 	661 	730 	680 	2,672 	-2
% Pharmaceutical Sales 	4.3% 	4.3% 	4.6% 	4.9% 	4.8% 	4.7%
Asia Pacific (other than China and Japan) 	535 	580 	595 	669 	612 	2,457 	-8
% Pharmaceutical Sales 	3.9% 	4.1% 	4.1% 	4.5% 	4.4% 	4.3%
Eastern Europe/Middle East/Africa 	435 	395 	353 	400 	348 	1,495 	10
% Pharmaceutical Sales 	3.2% 	2.8% 	2.4% 	2.7% 	2.5% 	2.6%
Canada 	125 	138 	143 	133 	144 	558 	-9
% Pharmaceutical Sales 	0.9% 	1.0% 	1.0% 	0.9% 	1.0% 	1.0%
Other 	324 	255 	231 	249 	355 	1,089 	27
% Pharmaceutical Sales 	2.4% 	1.9% 	1.6% 	1.5% 	2.5% 	1.7%
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
(1) Europe represents all European Union countries, the European Union accession markets and the United Kingdom.
(2) Gardasil/Gardasil 9 sales in China were $193 million in the first quarter of 2025 and $1,253 million, $1,312 million, $517 million and $446 million in
the first, second, third and fourth quarter of 2024, respectively.
7

-- 8 of 9 --

OTHER (INCOME) EXPENSE, NET
1Q25 	1Q24
Interest income 	(109)	$ 	(73)	$
Interest expense 	313 	303
Exchange losses 	90 	83
Income from investments in equity securities, net (1) (90) 	(143)
Net periodic defined benefit plan (credit) cost other than service cost 	(148) 	(160)
Other, net 	(91) 	(43)
Total 	(35)	$ 	(33)	$
(1) Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through
ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at
the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one
quarter lag.
MERCK & CO., INC.
OTHER (INCOME) EXPENSE, NET - GAAP
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 4
8

-- 9 of 9 --